Pfizer to Discontinue Agreement on REMOXY™ (oxycodone) Extended-Release … -…

NEW YORK, Oct 27, 2014 (BUSINESS WIRE) — Pfizer Inc. (NYSE:PFE) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE) that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics, Inc.

Pfizer has concluded an internal review (more…)

Pfizer Inc. Continues Development Program for Remoxy® (oxycodone … – Business Wire…

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year, Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received (more…)

Pain Therapeutics – Another Oxycodone Remix – Seeking Alpha

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Collaborations and reinvention are common in the development (more…)